GovChime
Notice ID: 8374bf4e03164f8c9bbda32c6dbb1212Award NoticeAwarded

Q--Medical Expert Services for the Western Regions (5

Awarded on April 22, 2021. Full description on SAM.gov.

Awarded tounder 28321321DMW060001 (source: SAM.gov award notice)• $14.1M

Overview

Posted
April 22, 2021
Notice type
Award Notice
NAICS
541611: Administrative Management and General Management Consulting Services
Agency
Social Security Administration

Notice details

Last updated
Sep 9, 2025
Award date
Apr 22, 2021
Award amount (SAM.gov award notice)
$14.1M

Identifiers

Solicitation number
28321321R00000002
Notice ID
8374bf4e03164f8c9bbda32c6dbb1212
Award number (PIID)
28321321DMW060001

Description

Provide Medical Expert Consulting Services for the Western Regions (5, 7-10), and the National Hearing Center) in hearings before an Administrative Law Judge.

Full description on SAM.gov

Award Overview

Award Number

28321321DMW060001

Award Amount (SAM.gov award notice)

$14.1M

Award Date

Apr 22, 2021

Awardee

Awardee UEI

NJYDJV1ZXWM1

Original Solicitation

Notice ID: 8374bf4e03164f8c9bbda32c6dbb1212

Posted Date: Apr 22, 2021

Original Response Deadline: Not specified

Task Orders Under This IDV

Top 10 by total obligated

10
  • 28321325FM0030009
    MEDNICK ASSOCIATES, LLC
    Social Security AdministrationNAICS 541611
    $5.3MSigned Jun 16, 2026
  • 28321323FM0030007
    MEDNICK ASSOCIATES, LLC
    Social Security AdministrationNAICS 541611
    $5.2MSigned Aug 22, 2023
  • 28321325FM0030009
    MEDNICK ASSOCIATES, LLC
    Social Security AdministrationNAICS 541611
    $4.9MSigned Jul 3, 2025
  • 28321325FM0030009
    MEDNICK ASSOCIATES, LLC
    Social Security AdministrationNAICS 541611
    $4.9MSigned Jul 18, 2025
  • 28321324FM0030007
    MEDNICK ASSOCIATES, LLC
    Social Security AdministrationNAICS 541611
    $4.7MSigned Jul 9, 2024
  • 28321323FM0030007
    MEDNICK ASSOCIATES, LLC
    Social Security AdministrationNAICS 541611
    $3.8MSigned Mar 28, 2025
  • 28321323FM0030001
    MEDNICK ASSOCIATES, LLC
    Social Security AdministrationNAICS 541611
    $2.2MSigned Oct 25, 2022
  • 28321323FM0030001
    MEDNICK ASSOCIATES, LLC
    Social Security AdministrationNAICS 541611
    $2.2MSigned Jan 1, 2023
  • 28321323FM0030001
    MEDNICK ASSOCIATES, LLC
    Social Security AdministrationNAICS 541611
    $2.0MSigned Apr 11, 2025
  • 28321326FM0030006
    MEDNICK ASSOCIATES LLC
    Social Security AdministrationNAICS 541611
    $2.0MSigned Sep 1, 2026

More From This Vendor

Top 5 most recent

5
  • 28321326FM0030006
    MEDNICK ASSOCIATES LLC
    Social Security AdministrationNAICS 541611
    $2.0MSigned Sep 1, 2026
  • 28321326FM0030006
    MEDNICK ASSOCIATES LLC
    Social Security AdministrationNAICS 541611
    $163.4KSigned Aug 21, 2026
  • 28321325FM0030009
    MEDNICK ASSOCIATES, LLC
    Social Security AdministrationNAICS 541611
    $5.3MSigned Jun 16, 2026
  • 28321321DMW060001
    MEDNICK ASSOCIATES, LLC
    Social Security AdministrationNAICS 541611
    —Signed Aug 8, 2025
  • 28321325FM0030010
    MEDNICK ASSOCIATES, LLC
    Social Security AdministrationNAICS 541611
    $10.0KSigned Aug 1, 2025

Contacts

Documents

No documents available.

Lifecycle

Solicitation:28321321R00000002
  1. Pre-Solicitation
  2. Solicitation
  3. Awarded

This opportunity has been awarded.

  1. Pre-SolicitationAug 21, 2020

    Q--Presolicitation Notice - Medical Expert Services

    Notice a315fc0a455b4e99b5cc9f3863e29068 on SAM.gov

  2. 2×
    SolicitationSep 23, 2020

    Q--Medical Expert Services for the Western Regions

    Notice 65d61c7e407544659d8340da7eaf19f7 on SAM.gov

  3. AwardedCurrentApr 22, 2021

    Q--Medical Expert Services for the Western Regions (5

    Notice 8374bf4e03164f8c9bbda32c6dbb1212 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
This Request for Information (RFI) is issued in accordance with FAR Part 10 to conduct market research. The Government's purpose is planning only; this notice does not constitute a Request for Proposal (RFP)/Request for Quotation (RFQ) nor a promise to issue one in the future. The Government will not pay any costs for responding, and any submissions become Government property and will not be returned. Not responding to this RFI does not preclude participation in any future procurement. The Government is not seeking proposals or quotes at this time. Scope of Interest / Functional Areas: The Government is assessing the market¿s capability to provide comprehensive support under the following disciplines: a. Audits for Medicare Parts A, B, D, and Medicaid medical record review and consultative services b. Audits for Medicare Part C medical record review and consultative services c. Evaluations and Inspections medical record review and consultative services d. Expert consultant and witness services in support of the Office of Investigations and/or Office of Counsel to the Inspector General A draft Performance Work Statement (PWS) is provided for industry feedback; requirements may change prior to any future solicitation. Requested Information (do not submit proposals or quotes): Please provide high level, non price specific information addressing the elements below. Do not include proprietary pricing, line item estimates, or any proposal/quote content. Section 1: Corporate Capability & Experience a. PWS Alignment: Demonstrate your organization's core capability to fulfill the functional areas outlined in the draft PWS. b. Medical Review Experience: Outline your firm's high-level experience in conducting large-volume medical claims reviews for audits and evaluations and inspections; and support services for medical expert consultants and witnesses specifically across the following five domains (as referenced in the attached PWS): 1. Audit Medicare Parts A/B/D and Medicaid 2. Audit Medicare Part C 3. Evaluations and Inspections 4. Office of Investigations 5. Office of Counsel to the Inspector General c. Geographic Reach: Describe your prior experience managing and executing nationwide or multi-jurisdictional medical claim reviews. d. Capacity & Scalability: State your organization's maximum monthly claim review capacity, including your approach to scaling operations between normal workloads and surge conditions. e Teaming & Subcontracting: Identify potential subcontracting partners or specialized vendors you would anticipate utilizing, including an estimated percentage breakdown of work performed by the prime contractor versus subcontractors. Section 2: High-Level Technical Approach & Operations a. High-Level Technical Methodology: Describe your conceptual approach to fulfilling the core tasks in PWS. Please limit this narrative to no more than 5 pages total, organized by the 5 PWS sections. Focus on your overarching claims review methodology, general sampling plan frameworks, documentation standards, and typical project timelines rather than a granular, step-by-step solution. b. Quality & Accuracy Frameworks: Outline your corporate quality assurance processes, internal review protocols, and standard strategies used to reduce error rates and ensure consistency across large volumes. b. Staffing & Key Qualifications: Provide a conceptual staffing structure or organizational chart. Identify the typical roles, credentials (e.g., MD, RN, CPC), and qualifications of the key personnel required to successfully support a PWS of this nature. Please identify whether these staff will need to be hired or if they are current employees/contractors. Also, indicate staffing availability for physicians with specialties (i.e. hospice, vascular surgeon, nephrologist, physical medicine and rehabilitation or physiatrists). c. Risk & Mitigation: Identify the primary technical or operational challenges anticipated with a medical review scope of this size and outline your high-level mitigation strategies. Section 3: Past Performance & Market Pricing a. Relevant Past Performance: Provide up to three examples of similar Federal medical review contracts performed within the last five years. Also, provide up to three examples of similar Federal support services for medical expert consultants and witnesses within the last five years. b. Performance Outcomes: Summarize the high-level outcomes of those past contracts, focusing on standard metrics such as timeliness, accuracy rates (including rate at which findings were overturned during the appeals process), and a history of successful audit findings. c. Cost Drivers & Efficiencies: Provide a general overview of your commercial pricing structure and the primary cost drivers (e.g., specific labor categories, specialized technology/AI tools, administrative overhead). Highlight any built-in efficiencies or innovative workflows in your approach that typically yield cost savings for the government. Section 4: Industry Feedback & PWS Refinement a. Clarity & Feasibility Review: Identify any requirements, metrics, or tasks within the draft PWS that appear ambiguous, overly restrictive, or technologically infeasible based on current commercial market capabilities. b. Recommendations for Improvement: Suggest specific enhancements, industry standard metrics, or structural changes to the PWS that would improve the clarity, feasibility, and competitiveness of the final solicitation. Submission Instructions: Email responses by November 13, 2026, 12:00 PM Eastern Time to the Points of Contact below. Mark proprietary information clearly; the Government may use non proprietary information to refine its acquisition approach. Points of Contact: a. Contracting Officer: Shavonda Jamison ¿ Shavonda_Jamison@ibc.doi.gov b. Contracting Specialist: Dorothy Royster ¿ Dorothy_Royster@ibc.doi.gov Attachments: a. Draft PWS (for market research and feedback only; subject to change). Disclaimer: This RFI is for market research; it does not commit the Government to any acquisition. The Government will not reimburse costs for responding. Not responding does not preclude participation in any future solicitation. No proposals or quotes will be accepted in response to this notice.
46%
Market Research11/13/2026
Services to manage the Ticket To Work Program (Ticket Program Manager Contract) including recruiting and monitoring Employment Networks (ENs), facilitation of beneficiary access to ENs, managing a contact center and program website, and EN payment administration. This is a cost-plus-award-fee (CPAF) term type contract with a one-year base period and four one-year option periods.
46%
AwardedOpen
The Office of the Army Surgeon General, Medical Education Directorate (MEDED) has formal oversight of Continuing Medical Education (CME) for Medical Corps (MC) Officers. The Contractor shall provide guidance to the Continuing Medical Education staff regarding the Army’s adherence to the Accreditation Council for Continuing Medical Education (ACCME) Requirements. The contractor shall provide consultative assistance and recommendations for the U.S. Army Medical Command (MEDCOM) and MEDED to attain the goal of a six-year reaccreditation.
43%
Solicitation11/20/2026
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood Cholestatic Liver Diseases The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) of the Department of Health and Human Services (DHHS) seeks industry collaborators to provide novel therapeutic agents, diagnostic markers, biomarkers and devices for use in NIH-sponsored multi-center clinical trials and ancillary studies in patients with childhood cholestatic liver diseases, including biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, and idiopathic neonatal hepatitis; and the liver disease related complications emanating from these diseases. BACKGROUND: The Childhood Liver Disease Research and Education Network (ChiLDReN) is a multi-center consortium of 10 clinical sites in the United States plus a scientific data coordinating center funded by NIDDK to study rare childhood liver diseases that result in cholestasis, including primary sclerosing cholangitis, biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, and idiopathic neonatal hepatitis. Five ongoing studies being conducted by ChiLDReN include: 1) A Prospective Database of Infants with Cholestasis (PROBE), a longitudinal observational study starting in infancy which has enrolled 890 infants with biliary atresia and 621 with intrahepatic cholestasis; 2) Biliary Atresia Study in Infants and Children (BASIC), a longitudinal study of children with biliary atresia both before and after liver transplant, which has enrolled over 1768 children with biliary atresia 3) Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC), a longitudinal study of intrahepatic cholestasis diseases, which has enrolled 474 subjects with Alagille syndrome, 572 with alpha-1 antitrypsin deficiency liver disease, 355 with PFIC and 36 with bile acid defects; 4) Longitudinal study of Mitochondrial Hepatopathies (MITOHEP) with 73 participants; and 5) Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH), a study of the prognostic value of hepatic ultrasound on the development of liver fibrosis in CF, which has enrolled over 770 subjects. In addition, ChiLDReN completed a placebo-controlled clinical trial to determine if post-operative corticosteroid therapy improves serum bilirubin and survival without liver transplantation in 140 infants with biliary atresia who have undergone the Kasai surgery ("START"). Ancillary studies to evaluate the natural history, clinical outcomes and quality of life, pathogenesis, genetics and genomics, proteomics, metabolomics, lipidomics, imaging studies, and determinants of progression and severity of these cholestatic liver diseases present a variety of research collaboration opportunities. ChilDReN is also interested in conducting clinical trials of promising therapies to improve clinical outcomes for these cholestatic liver diseases. Finally, improved diagnostics or screening procedures for biliary atresia and cholestasis in infants are of great interest to ChiLDReN. STUDY GOALS: The overall goal of ChiLDReN is to determine the etiology, genetics, pathogenesis, natural history, clinical outcomes, complications, predictors of outcomes and optimal therapy of the cholestatic liver diseases. ChiLDReN studies have enrolled and are following a relatively large and well characterized population of children and young adults with these rare disorders. ChiLDReN is interested in conducting research that will lead to improved clinical outcomes in children and young adults with these cholestatic liver diseases with industry collaborators to: • Evaluate the natural history, pathogenesis, diagnosis, genetic factors, genomics, proteomics, metabolomics, lipidomics, epigenomics, imaging studies, and determinants of progression and severity of biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis. • Explore use of serum markers for fibrosis and serum markers for disease activity to predict hepatic histology either by themselves or in combination with other clinical, laboratory, genomic, proteomic, metabolomic, and lipidomic variables • Explore the utility of these serum markers as surrogate markers of therapeutic response in study subjects participating in treatment trials (e.g., START study for biliary atresia) • Investigate proprietary drugs (such as novel choleretic agents, anti-fibrogenic agents, autophagy inducers, chloride channel inducers, fat-soluble vitamin supplements, bone mineral density agents, etc.), reagents, or devices in controlled randomized clinical trials as potential diagnostics or therapies for biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis • Evaluate novel newborn or infant screening techniques or devices for biliary atresia or cholestasis. • Evaluate noninvasive imaging methods for assessing fibrosis, biliary disease, and parenchymal pathology in these diseases including but not limited to the use of elastography, nuclear magnetic resonance imaging, and molecular imaging. • Evaluate the use of cytokine assays for analyses of serum/plasma cytokine levels as markers of disease activity and as surrogate markers of histologic or clinical improvement in therapeutic trials CAPABILITY STATEMENT: Commercial organizations interested in pursuing clinical collaborations with NIDDK for childhood cholestatic liver diseases are required to submit a Capability Statement to NIDDK. The Capability Statements submitted in response to this announcement will be used to evaluate and select industry collaborators. The Capability Statement should not exceed 10 (ten) pages of narrative (not including appendices) and should include the following information: 1. A description of the therapeutic, diagnostic or device proposed to be used in the clinical research study. (Note: The proposed therapeutic or device must have been tested already in a Phase I trial in humans.) 2. The specific details of the methods to be utilized in the investigation of the pharmacologic, surgical or device intervention in patients with biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis, and a clear description of all important issues surrounding the evaluation of disease progression in these patients. 3. A detailed plan demonstrating the ability to provide sufficient quantities of the therapeutic, diagnostic or device in a timely manner for the duration of the study. 4. A description of all laboratory tests that are needed, including assays and required amount of specimens, to determine specific biomarker levels along with appropriate methods for performing such tests. 5. A description of other core facilities and interactions with core facilities that are needed for the study. 6. Dosing and pharmacokinetic data from human studies for any novel therapeutics. 7. Adverse event profile for the proposed therapeutic or device. 8. A description of the practices and procedures that would be used to assure patient privacy and maintain confidentiality of data obtained from the study. 9. (Optional) Outcome measures of interest to the organization. The specifics of the proposed outcome measures should include but not be limited to treatment and evaluation of biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis. 10. Any other resources the organization proposes to commit to the collaboration (in addition to the proposed therapeutic, diagnostic or device), which may include any of the following: equipment, reagents, supplies, access to facilities, personnel or services, and, if appropriate, funding (pursuant to a Cooperative Research and Development Agreement (CRADA) authorized under 15 U.S.C. § 3710a), to help support the conduct of the clinical study. 11. Affirmative statements that the organization: a. agrees to provide a Letter of Cross Reference to the Drug, Biologic or Device Master File for the proposed therapeutic or device, which will be included with any US FDA filing by the IND or IDE Sponsor of the ChiLDReN study; b. agrees to have the proposed therapeutic, diagnostic or device used in ChiLDReN-developed protocols which will be conducted by the ChiLDReN research network for which the study data collection and analysis will be performed by the ChiLDReN Scientific and Data Coordinating Center; c. agrees to assure patient privacy and will maintain confidentiality of data obtained from the study; d. agrees to share all safety data from other studies involving the proposed therapeutic or device as well as relevant efficacy data from other studies (updated Investigator Brochure, etc) with the ChiLDReN; e. understands that because the ChiLDReN network is supported by NIDDK funding, the study results will be published and therefore agrees to the prompt publication of research results from the clinical study using the organization's proposed therapeutic, diagnostic or device; and f. understands that the clinical study will be conducted under an agreement with NIDDK which must adhere to PHS intellectual property policies (see: http://www.ott.nih.gov/policy/phspat_policy.aspx). SUBMISSION: Capability Statements received by NIDDK will be considered. Prospective collaborators may be invited to attend, at their own expense, a ChiLDReN Steering Committee meeting to be held in the Baltimore-Washington, DC area to discuss the information in their Capability Statement with the Steering Committee members. NOTE:NO FUNDS WILL BE PROVIDED BY NIDDK TO ANY ORGANIZATION SELECTED FOR THIS CLINICAL RESEARCH COLLABORATION OPPORTUNITY. SUBMISION AND INQUIRIES: Submit Capability Statements to: NOO Coordinator, National Institute of Diabetes and Digestive and Kidney Diseases e-mail: niddkottdip@niddk.nih.gov For Scientific Inquiries contact: Edward Doo, MD Director, Liver Diseases Research Program Division of Digestive Diseases and Nutrition, NIDDK 6707 Democracy Blvd., Room 6149 Bethesda, MD 20892-5450 Telephone: (301) 451-4524 FAX: (301) 480-8300 e-mail: dooe@niddk.nih.gov Katrina Loh, MD Director, Pediatric Gastrointestinal and Liver Diseases Division of Digestive Diseases and Nutrition, NIDDK 6707 Democracy Blvd., Room 6148 Bethesda, MD 20892-5450 Telephone: (301) 827-1079 FAX: (301) 480-8300 e-mail: katrina.loh@nih.gov For Inquiries Regarding Partnering with NIDDK (Intellectual Property Matters and Collaboration Agreements) contact: Agnes Rooke, JD Technology Advancement Office NIDDK, NIH, HHS Telephone: 301-451-6072 e-mail: Agnes.Rooke@nih.gov This Notice of Opportunity is also posted at: http://techdev.niddk.nih.gov/collabs.shtml.
39%
Special Notice05/31/2029
FOOD AND DRUG ADMINISTRATION (FDA) Regulatory Support Services BPA SOURCES SOUGHT NOTICE (SSN) Description The U.S. Food and Drug Administration's (FDA), Office of Acquisitions and Grants Services (OAGS), is conducting market research for obtaining Regulatory Support Services. THIS IS A SOURCES SOUGHT NOTICE (SSN) ONLY. This SSN is being issued in accordance with Federal Acquisition Regulation (FAR) Part 10, Market Research. It is for information, planning and market research purposes only and is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. The Government reserves the right to contact any of the respondents after the submission deadline if additional information is required. The purpose of this SSN is to identify and gain knowledge of potential business sources and small business sources that are capable of providing the full range of services described in this SSN and the attached Draft Statement of Work (SOW). Responses to this SSN will be utilized for a potential solicitation for an anticipated stand-alone BPA for Regulatory Support Services Program. The anticipated period of performance for this contract is a Fiscal Year 2027 award with a base year, plus four (4) option years), with a potential 6-month extension of services pursuant to FAR 52.217-8. Requested Information Interested parties are highly encouraged to respond to this SSN by providing the following information in their response: Completed Vendor Feedback Form – See attached Vendor Feedback Form If applicable, tracked changes/comments on draft SOW in MS Word format – See attached Draft SOW Capability Statement Responses shall be submitted via email with the subject line "Sources Sought Notice - FDA SSN: CTP-2027-136871” to the Contracting Officer, Nicholas Bisher (Nicholas.Bisher@fda.hhs.gov), no later than 5:00pm (Eastern) on November 24, 2026. Attachments Vendor Feedback Form Draft Statement of Work
35%
Market Research11/24/2026

Additional Details

Solicitation Number

28321321R00000002

Archive Date

May 10, 2021

Office Address

BALTIMORE, MD, 21235